EirGenix, Inc.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.eirgenix.com
Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- EirGenix, Inc.
- Target Recruit Count
- 380
- Registration Number
- NCT06884254
- Locations
- 🇺🇸
Methodist Health System Clinical Research Institute, Dallas, Texas, United States
A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: 420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- EirGenix, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT05471648
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- EirGenix, Inc.
- Target Recruit Count
- 807
- Registration Number
- NCT03433313
- Locations
- 🇨🇴
Clinic Life Foundation, Medellín, Colombia
🇬🇪LTD High-Tech Hospital MedCenter, Batumi, Georgia
🇬🇪LTD Institute of Clinical Oncology, Tbilisi, Georgia
A Pharmacokinetic Study Comparing EG12014 and Herceptin (Trastuzumab) in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: EG12014Biological: EU-sourced HerceptinBiological: US-sourced Herceptin
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- EirGenix, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT03180242
© Copyright 2025. All Rights Reserved by MedPath